Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

Phase 4 Completed 50 enrolled Stephenson Eye Associates

RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, controlled, double-masked, investigator-initiated trial to evaluate tear film quality and stability in subjects with dry eye disease using OC-01 (varenicline solution) nasal spray 0.03 mg as compared to vehicle control nasal spray.

Timeline

Start: 2022-10-11
Primary completion: 2023-12-05
Completion: 2023-12-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	0.03 mg	Intranasal

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

Summary

Timeline

Drugs

Indications